New Vaccine Introduction Framework
On this page
Direct answer
No vaccine walks into India's Universal Immunisation Programme uninvited: a new antigen arrives through a defined framework that runs from disease-burden evidence to post-introduction evaluation, with the National Technical Advisory Group on Immunisation (NTAGI) — India's counterpart to WHO's SAGE — at the decision centre. A candidate vaccine must justify itself on burden and cost-effectiveness, supply security and affordability, cold-chain and waste-management compatibility, and safety surveillance capacity; after government acceptance it typically enters phased — rotavirus from 2016 in four states before national scale, pneumococcal conjugate from 2017, measles-rubella through campaign mode from 2017 — accompanied by guideline revisions, training, microplans and communication. After the rollout, a post-introduction evaluation (PIE) audits coverage, logistics and adverse-event reporting, feeding corrections into the next introduction.
What you must remember
- Who decides: NTAGI, supported by standing technical sub-groups and secretariat input from ICMR, MoHFW and partners; the global reference body is WHO's SAGE — name both in viva.
- Evidence package: disease burden (surveillance, Indian studies), vaccine efficacy and safety, delivery feasibility, cold-chain impact, introduction cost and cost-effectiveness, and exit conditions for alternatives.
- Phased introductions to quote: pentavalent vaccine from 2011 (Kerala and Tamil Nadu first) expanding nationally; rotavirus 2016 in four states, national by 2019; pneumococcal conjugate 2017 phased; measles-rubella switch through campaign-plus-routine from 2017; Japanese encephalitis expanded in endemic districts from the mid-2000s.
- Cold-chain discipline: nearly all UIP vaccines at 2-8 degrees Celsius, with OPV the classic heat-sensitive exception (minus 20 for long storage); DPT, TT and IPV are freeze-sensitive — a viva pairing.
- Campaign-introduction hybrid: measles-rubella used a wide-age-range campaign to close the susceptibility gap before routine two-dose scheduling — the "catch-up campaign" strategy.
- Safety layer: AEFI surveillance strengthens with every introduction; every new antigen demands trained reporting, causality assessment committees and communication preparedness for events.
- PIE: post-introduction evaluation is the formal audit — coverage achieved, logistics, waste management, AEFI and acceptance — conducted within the first year or so.
Two introductions, two lessons
Set rotavirus and pneumococcal conjugate side by side. Both target pneumonia-diarrhoea burden, both entered phased in 2016-17, and both illustrate the framework's sequencing: NTAGI recommendation building on Indian disease-burden data, Gavi-supported supply negotiation, cold-chain volume calculations at state level, training of vaccinators on dilution or presentation changes, and staggered state launches so errors surface early on a small stage. The measles-rubella introduction teaches a different lesson: when the routine schedule already contains a closely related antigen (measles), a campaign across a wide age band — nine months to under fifteen years in successive states — collapses the susceptible population first, preventing gap years in which older children would never have been reached by routine dosing alone.
Introduction is not an event but a system stress test: every new vial occupies cold-chain space, every diluent changes session workflow, every new injection alters drop-out risk, and every fever in a vaccinated child becomes a potential headline. Hence PIE: it converts a press release into a learning document whose findings shape NTAGI's next decision.
Where candidates lose marks
The recurring failure is treating introduction as "government announces vaccine". The structured answer runs: burden evidence, NTAGI process, cold-chain and supply preparedness, training and communication, phased or campaign rollout, AEFI readiness, then PIE — seven links, and each is mark-bearing. A second slip is dating: rotavirus 2016, PCV 2017, MR campaign 2017 onward, pentavalent 2011 — examiners deliberately ask which came first. Third, the IPV story deserves its own line: after India's polio-free certification on 27 March 2014, the trivalent-to-bivalent OPV switch of April 2016 required introducing one IPV dose into the routine schedule as a risk-mitigation step — the clearest example of a global eradication strategy driving a national introduction. Finally, be ready for the ethical-resource question: with every addition raising programme cost, NTAGI's implicit task is deciding which preventable deaths to avert first — a framing that distinguishes a professional answer from a worksheet answer.
Frequently asked questions
Which body recommends new vaccines for India's UIP?
The National Technical Advisory Group on Immunisation (NTAGI), with technical sub-committees, examines burden, efficacy and feasibility evidence and recommends introduction to the Ministry of Health and Family Welfare.
What is post-introduction evaluation?
A structured audit conducted after a vaccine's rollout — assessing coverage, cold-chain and wastage, AEFI reporting, and community acceptance — whose findings refine the introduction and future decisions.
How were rotavirus and pneumococcal vaccines introduced?
Both entered phased: rotavirus in 2016 in four states before national scale-up by 2019, and pneumococcal conjugate from 2017 in a staggered state-by-state expansion.
Why did the MR introduction use campaigns?
A wide-age-band measles-rubella campaign first closed the susceptibility gap among older children before the routine two-dose schedule took over, preventing cohorts that routine dosing alone would have missed.
What cold-chain facts accompany introductions?
Most UIP vaccines store at 2-8 degrees Celsius; OPV is the heat-sensitive exception stored below minus 20 long-term, while DPT, TT and IPV are freeze-sensitive — introductions must fit these physical constraints.